IRadimed Statistics
Total Valuation
IRadimed has a market cap or net worth of $525.13 million. The enterprise value is $477.41 million.
| Market Cap | 525.13M |
| Enterprise Value | 477.41M |
Important Dates
The next confirmed earnings date is Thursday, May 2, 2024, before market open.
| Earnings Date | May 2, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
IRadimed has 12.66 million shares outstanding. The number of shares has increased by 0.69% in one year.
| Shares Outstanding | 12.66M |
| Shares Change (YoY) | +0.69% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 37.10% |
| Owned by Institutions (%) | 54.90% |
| Float | 6.54M |
Valuation Ratios
The trailing PE ratio is 30.72 and the forward PE ratio is 26.57. IRadimed's PEG ratio is 4.46.
| PE Ratio | 30.72 |
| Forward PE | 26.57 |
| PS Ratio | 8.01 |
| Forward PS | 7.04 |
| PB Ratio | 7.35 |
| P/FCF Ratio | 96.21 |
| PEG Ratio | 4.46 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.21, with an EV/FCF ratio of 87.47.
| EV / Earnings | 27.77 |
| EV / Sales | 7.28 |
| EV / EBITDA | 21.21 |
| EV / EBIT | 21.96 |
| EV / FCF | 87.47 |
Financial Position
The company has a current ratio of 4.66, with a Debt / Equity ratio of 0.03.
| Current Ratio | 4.66 |
| Quick Ratio | 3.80 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.09 |
| Debt / FCF | 0.37 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 24.60% and return on invested capital (ROIC) is 21.57%.
| Return on Equity (ROE) | 24.60% |
| Return on Assets (ROA) | 20.40% |
| Return on Capital (ROIC) | 21.57% |
| Revenue Per Employee | $442,988 |
| Profits Per Employee | $116,167 |
| Employee Count | 148 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 1.69 |
Taxes
In the past 12 months, IRadimed has paid $4.55 million in taxes.
| Income Tax | 4.55M |
| Effective Tax Rate | 20.91% |
Stock Price Statistics
The stock price has increased by +3.19% in the last 52 weeks. The beta is 0.86, so IRadimed's price volatility has been lower than the market average.
| Beta (1Y) | 0.86 |
| 52-Week Price Change | +3.19% |
| 50-Day Moving Average | 42.87 |
| 200-Day Moving Average | 43.92 |
| Relative Strength Index (RSI) | 46.08 |
| Average Volume (30 Days) | 57,327 |
Short Selling Information
The latest short interest is 104,883, so 0.83% of the outstanding shares have been sold short.
| Short Interest | 104,883 |
| Short Previous Month | 108,394 |
| Short % of Shares Out | 0.83% |
| Short % of Float | 1.60% |
| Short Ratio (days to cover) | 2.35 |
Income Statement
In the last 12 months, IRadimed had revenue of $65.56 million and earned $17.19 million in profits. Earnings per share was $1.35.
| Revenue | 65.56M |
| Gross Profit | 50.16M |
| Operating Income | 20.04M |
| Pretax Income | 21.74M |
| Net Income | 17.19M |
| EBITDA | 22.50M |
| EBIT | 21.74M |
| Earnings Per Share (EPS) | $1.35 |
Balance Sheet
The company has $49.76 million in cash and $2.04 million in debt, giving a net cash position of $47.72 million or $3.77 per share.
| Cash & Cash Equivalents | 49.76M |
| Total Debt | 2.04M |
| Net Cash | 47.72M |
| Net Cash Per Share | $3.77 |
| Equity / Book Value | 71.42M |
| Book Value Per Share | 5.64 |
| Working Capital | 59.67M |
Cash Flow
In the last 12 months, operating cash flow was $13.47 million and capital expenditures -$8.01 million, giving a free cash flow of $5.46 million.
| Operating Cash Flow | 13.47M |
| Capital Expenditures | -8.01M |
| Free Cash Flow | 5.46M |
| FCF Per Share | $0.43 |
Margins
Gross margin is 76.50%, with operating and profit margins of 30.56% and 26.22%.
| Gross Margin | 76.50% |
| Operating Margin | 30.56% |
| Pretax Margin | 33.16% |
| Profit Margin | 26.22% |
| EBITDA Margin | 34.32% |
| EBIT Margin | 33.16% |
| FCF Margin | 8.32% |
Dividends & Yields
IRadimed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.69% |
| Shareholder Yield | -0.69% |
| Earnings Yield | 3.27% |
| FCF Yield | 1.04% |
Analyst Forecast
The average price target for IRadimed is $65.00, which is 56.74% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $65.00 |
| Price Target Difference | 56.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
IRadimed has an Altman Z-Score of 18.12 and a Piotroski F-Score of 5.
| Altman Z-Score | 18.12 |
| Piotroski F-Score | 5 |